Kuo, Hung-Yang http://orcid.org/0000-0002-0573-2636
Khan, Kabir A. http://orcid.org/0000-0001-8453-3485
Kerbel, Robert S. http://orcid.org/0000-0002-6015-2570
Article History
Accepted: 18 March 2024
First Online: 10 April 2024
Competing interests
: R.S.K. has received research funding from Genentech and Novelty Nobility, and is a consultant for Novelty Nobility, OncoHost and PharmAbcine. H.-Y.K. and K.A.K. declare no competing interests.